Oncolytics Biotech (ONCY) Registration Filing summary

Company overview and business model

• Focuses on research and development of pelareorep, an intravenously delivered immunotherapeutic agent for cancer treatment, with no commercialized products to date.

• Operates as a development-stage biotech company, expecting continued losses until pelareorep becomes commercially viable.

• Headquartered in Calgary, Alberta, with material subsidiaries in Barbados and the U.S.

Financial performance and metrics

• Incorporated financials include audited statements for years ended December 31, 2023, 2022, and 2021, and unaudited interim results as of March 31, 2024.

• Since March 31, 2024, issued 1,566,265 common shares at a weighted average price of US$1.10 per share.

• Outstanding common shares total 76,986,033, with potential to increase to 84,595,868 upon exercise of all options and awards.

Use of proceeds and capital allocation

• Proceeds from securities offerings will be described in the relevant prospectus supplement for each issuance.